Author

C. S. Stipp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Varzavand· 2 shared M. D. Henry· 2 shared A. C. Rowat· 1 shared A. Goeken· 1 shared A. J. Dupuy· 1 shared A. J. Klingelhutz· 1 shared A. P. Voigt· 1 shared B. L. Krog· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Varzavand

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ISG15-modification of the Arp2/3 complex restricts pathogen spread

Y. Zhang, B. M. Ripley, W. Ouyang, M. Sturtz, E. Upton, E. Luhmann, M. Vessely, R. Coloma, N. Schwery, S. M. Anthony, A. Goeken, T. O. Moninger, J. T. Harty, A. J. Klingelhutz, E. Lundberg, , L. Radoshevich

This study shows ISG15 modifies the Arp2/3 complex to restrict pathogen spread by slowing actin filament formation and stabilizing structures, but pathogens like Listeria exploit dysregulated ISGylation to enhance spread.

bioRxiv · Dec 27, 2022 · PreprintCell Biology

Abl kinase deficiency promotes AKT pathway activation and prostate cancer progression and metastasis

M. A. Marchal, D. Moose, A. Varzavand, D. Taylor, J. A. Brown, M. D. Henry, C. S. Stipp

bioRxiv · May 19, 2020 · PreprintCancer Biology

Cancer cells resist mechanical destruction in the circulation via RhoA-myosin II axis

D. L. Moose, B. L. Krog, L. Zhao, T.-H. Kim, S. Williams-Perez, G. Burke, L. Rhodes, M. Vanneste, P. Breheny, M. Milhem, C. S. Stipp, A. C. Rowat, M. D. Henry

This study identifies the RhoA-myosin II axis as a mechanism enabling cancer cells to resist mechanical destruction by hemodynamic forces in circulation.

bioRxiv · Apr 6, 2019Cancer Biology

Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

C. R. Feddersen, J. L. Schillo, A. Varzavand, H. R. Vaughn, L. S. Wadsworth, A. P. Voigt, E. Y. Zhu, B. M. Jennings, S. A. Mullen, J. Bobera, J. D. Riordan, C. S. Stipp, A. J. Dupuy

This study identifies DBL family members as drivers of vemurafenib resistance in melanoma and shows that Src inhibition can block this resistance.

bioRxiv · Feb 26, 2019Cancer Biology